Jing Hu

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood · 2015 · 181 citations · Full text

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells

Hongyu Li, Jing Hu, Shuhong Wu et al. · Oncotarget · 2015 · 145 citations · Full text

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Blood · 2016 · 139 citations · Full text

Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway

Dehai Che, Shuai Zhang, Zihan Jing et al. · Molecular Immunology · 2017 · 129 citations

TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway

Ying Xing, Yuechao Liu, Tianbo Liu et al. · Cell Communication and Signaling · 2018 · 101 citations · Full text